Journal
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
Volume 11, Issue 2, Pages 490-501Publisher
XIA & HE PUBLISHING INC
DOI: 10.14218/JCTH.2022.00277
Keywords
Biliary tract cancer; Drug therapy; Combination; Immunotherapy; Molecular targeted therapy; Clinical trials
Categories
Ask authors/readers for more resources
Biliary tract cancers (BTCs) have a poor prognosis and surgery is the only curative therapy. Currently, chemotherapy is the main treatment, but many patients develop resistance. Therefore, targeted therapy and immunotherapy have become important strategies to improve patient outcomes.
Biliary tract cancers (BTCs) are a group of malignant neoplasms that have recently increased in incidence and have a poor prognosis. Surgery is the only curative therapy. However, most patients are only indicated for palliative therapy because of advanced-stage disease at diagnosis and rapid progression. The current first-line treatment for advanced BTC is gemcitabine and cisplatin chemotherapy. Nonetheless, many patients develop resistance to this regimen. Over the years, few chemotherapy regimens have managed to improve the overall survival of patients. Accordingly, novel therapies such as targeted therapy have been introduced to treat this patient population. Extensive research on tumorigenesis and the genetic profiling of BTC have revealed the heterogenicity and potential target pathways, such as EGFR, VEGF, MEK/ERK, PI3K and mTOR. Moreover, mutational analysis has documented the presence of IDH1, FGFR2, HER2, PRKACA, PRKACB, BRAF, and KRAS gene aberrations. The emergence of immunotherapy in recent years has expanded the treatment landscape for this group of malignancies. Cancer vaccines, adoptive cell transfer, and immune checkpoint inhibitors have been extensively investigated in trials of BTC. Therefore, patient stratification and a combination of various therapies have become a reasonable and important clinical strategy to improve patient outcomes. This review elaborates the literature on combined treatment strategies for advanced BTC from the past few years and ongoing clinical trials to provide new inspiration for the treatment of advanced BTC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available